BIOLINERX
Careers | Contact Us
search

Press Releases
December 6, 2011

- BL-1021 was shown to be safe and well tolerated -
- Safety is a significant concern in current neuropathic pain treatments -

September 7, 2011
BioLineRx has signed an agreement with Ramot, the technology transfer company of Tel Aviv University, for the development and commercialization of BL-7050, a novel, orally-available treatment for neuropathic and inflammatory pain.
August 23, 2011

Dr. Kinneret Savitsky, "During the second quarter we continued developing, advancing and enriching our pipeline, while focusing on products in advanced clinical stages"

261-270  Out of  309 Previous
 1   2   3   4   5   6   7   8   9   10   11   12   13   14   15 
 16   17   18   19   20   21   22   23   24   25   26   27   28   29 
 30   31 
Next